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Background: Metaplastic carcinoma, an uncommon subtype of breast cancer, is part of the spectrum of basal-like,
triple receptor-negative breast carcinomas. The present study examined 20 surgical specimens of metaplastic breast
carcinomas, for the presence of high-risk Human papillomavirus (HPV), which is suspected to be a potential
carcinogenic agent for breast carcinoma.
Methods: Mastectomy specimens from patients harboring metaplastic breast carcinoma, as defined by the World
Health Organization (WHO), and who attended the Instituto Nacional de Cancerologia in Mexico City, were
retrieved from the files of the Department of Pathology accumulated during a 16-year period (1995–2008).
Demographic and clinical information was obtained from patients’ medical records. DNA was extracted from
formalin-fixed, paraffin-embedded tumors and HPV type-specific amplification was performed by means of
Polymerase chain reaction (PCR). Quantitative Real-time (RT) PCR was conducted in HPV positive cases. Statistically,
the association of continuous or categorical variables with HPV status was tested by the Student t, the Chi square,
or Fisher’s exact tests, as appropriate.
Results: High-risk HPV DNA was detected in eight (40%) of 20 metaplastic breast carcinomas: seven (87.5%) HPV-16
and one (12.5%) HPV-18. Mean age of patients with HPV-positive cases was 49 years (range 24–72 years), the same
as for HPV-negative cases (range, 30–73 years). There were not striking differences between HPV + and HPV–
metaplastic carcinomas regarding clinical findings. Nearly all cases were negative for estrogen, progesterone and
Human epidermal growth factor receptor 2 (HER2), but positive for Epidermal growth factor receptor (EGFR).
Conclusions: High-risk HPV has been strongly associated with conventional breast carcinomas, although the subtle
mechanism of neoplastic transformation is poorly understood. In Mexican patients, the prevalence of HPV infection
among metaplastic breast carcinomas is higher than in non-metaplastic ones, as so the HPV viral loads;
notwithstanding, HPV viral loads show wide variation and remain even lower than cervical and other non-cervical
carcinomas, making it difficult to assume that HPV could play a key role in breast carcinogenesis. Further studies are
warranted to elucidate the meaning of the presence of high-risk HPVDNA in breast carcinomas.
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Metaplastic carcinoma is an uncommon subtype of breast
cancer that encompasses two subgroups of malignant neo-
plasms: those with epithelial differentiation (i.e., squamous
cell carcinoma, adenocarcinoma with spindle cell differen-
tiation, and adenosquamous carcinoma), and those with
benign or malignant mesenchymal components (i.e., car-
cinoma with chondroid and/or osseous metaplasia, and
carcinosarcoma) [1]. According to the National Cancer
Data Base [2] metaplastic breast carcinoma represents
0.24% of total breast carcinomas in the U.S. It has been
widely recognized that metaplastic carcinomas display an
aggressive biological behavior and entertain a worse prog-
nosis, when they are compared with usual breast carcin-
omas, as evidenced by the high percentage of lymph node
metastases at the time of diagnosis, high mortality rate
due to disease persistence, high p53 and Ki-67 indexes,
and low, if any, expression of hormonal receptors and c-
erbB2 oncoprotein [3]. Metaplastic carcinomas are usually
sporadic and some cases have been related with pre-
existing benign fibrosclerotic-epithelial lesions [4]. Recently,
it has been proposed that metaplastic breast carcinomas,
together with salivary gland-like tumors and poorly differ-
entiated ductal and medullary carcinomas, may actually
represent the spectrum of basal-like breast carcinomas
[5,6]. According to the transcriptional profiling-based new
molecular classification of breast carcinomas, basal-like car-
cinomas are considered a subtype of triple receptor- nega-
tive cancers, the other subtype comprising the normal
breast-like carcinoma [7]. Immunohistochemically, basal-
like carcinomas are accurately classified by showing nega-
tivity for estrogen, progesterone and Human Epidermal
growth factor receptors (Estrogen receptors [ER], Proges-
terone receptors [PgR], and Human epidermal growth
factor receptor 2 [HER2], respectively), as well as for
expressing basal cytokeratin 5/6; this panel identifies basal-
like breast cancers with 100% specificity and 76% sensitivity
[8]. Despite the similarities regarding gene expression pat-
terns and surrogate immunohistochemical profiling, basal-
like carcinomas constitute a heterogeneous subgroup of
breast carcinomas that warrants further revaluation [9].
Notwithstanding the molecular approach to breast carcino-
genesis, the etiology of breast cancer remains poorly
understood. Among etiologic factors, high-risk Human
papillomavirus (HPV) has been strongly advocated as a
potential carcinogenic agent since 1992 by Di Lonardo
et al. [10], who reported the presence of HPV-16 Deoxy-
ribonucleic acid (DNA) in nearly 30% of ductal breast car-
cinomas, by means of Polymerase chain reaction (PCR).
Since then, HPV-status has been rarely studied in breast
carcinomas other than ductal and lobulillar ones. In a
series of 27 pure or metaplastic squamous cell carcinomas
of the mammary gland, Grenier et al. [11] found HPV
DNA in two of 14 (7.4%) metaplastic breast carcinomas.The aim of the present study was to look for high-risk
HPV DNA sequences in a set of metaplastic breast carcin-
omas from Mexican patients attending the Instituto
Nacional de Cancerología, in Mexico City.
Methods
This is an observational and descriptive study considered
by the Mexican regulation in health research as a safely
study that does not need informed consent [12]. The study
was approved by the Committee on Ethics in Research, at
the Instituto Nacional de Cancerología, México.
Study subjects
Formalin-fixed, paraffin-embedded metaplastic breast car-
cinomas obtained from Mexican patients attending the
Instituto Nacional de Cancerología, were retrieved from
the files of the Department of Pathology accumulated dur-
ing a 16-year period (1995–2008). Demographic and clin-
ical information was obtained from patients’ medical
records. Histologic classification was assessed as proposed
by the World Health Organization (WHO) classification
of breast tumors [1].
DNA extraction
Twenty-μm sections of formalin-fixed, paraffin-embedded
tumors were dewaxed through incubation with N-octane
and washings with 100% ethanol. This process was re-
peated twice, after which the pellet was dried. The de-
paraffinized sample was digested with 1 ml of lysis buffer
(Tris-Cl 10 mM pH 8.0, EDTA 0.1M pH 8–0, SDS 0.5,
Proteinase K 200 μg/ml, RNase A 20 μg/ml) at 55°C for 3
hr. DNA was extracted with phenol/chloroform preci-
pitations as described by Sambrook et al. [13] To test
DNA suitability for polymerase chain reaction (PCR)
amplification the DNA obtained was amplified for the β-
globin gene (PCO4/GH2O) under conditions described by
Resnick et al. [14] Samples were latter submitted to HPV
amplification with three sets of the following universal
primers recognizing distinct size fragments of the L1 gene:
L1C1/L1C2, MY09/MY11, and GP5/GP6 [15-17]. HPV
type-specific amplification was also performed with pri-
mers designed to amplify the E6 gene of HPV types-16
and −18 as described by Lizano et al. [18].
HPV PCR products were electrophoresed in a 1.2%
agarose gels and visualized by ethidium bromide staining.
HPV typing was performed through direct sequencing of
PCR products by means of BigDyeTM Terminator v3.1
Cycle Sequencing kit (Applied Biosystems). The resulting
sequences were analyzed in the Basic Local Alignment
Search Tool (BLAST) data bank for comparison with
known HPV sequences. HPV- 16 and-18 DNA amplifica-
tion was conducted for each sample, using specific primers
as previously described [17]. DNA extracted from Caski
and HeLa HPV-containing cell lines were used as positive
Table 1 Antibodies used in the present study
Antibody* Dilution Clone Source
ER 1:20 1D5 DakoCytomation
PgR 1:50 1294 DakoCytomation
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not separate episomal from chromosomal DNA. Usually,
episomal DNA extraction requires another technique
such as Hirt method that isolates low molecular weight
DNA. [19].Her2/neu 1:10 Herceptest DakoCytomation
EGFR 1:5 DAK-H1-1197 DakoCytomation
*ER, Estrogen receptors; PgR, Progesterone receptors; EGFR, Epidermal growth
factor receptor.Quantitative real-time PCR
As previously indicated, DNA was isolated just from neo-
plastic tissue. HPV physical status was not determined. To
estimate the copy numbers of HPV-16 genomes in biopsy
samples, the primers utilized to amplify the E6 oncogene
fragment were the following: E6-HPV16-648-Reverse:
GAACCGAAACCGGTTAGTAT, and E6-HPV16- 419-
Forward: GGACACAGTGGCTTTTGACA. Real-time
PCR assays were performed using SBYR GREEN (Ap-
plied Biosystems). PCR conditions were optimized to
300 nM E6-HPV16-648-Reverse primer and 300 nM
E6-HPV16-419- Forward primer. PCR reactions were
performed in a Rotor-Gene 6000 (Corbett Life Science)
with the following PCR conditions: 95°C for 30 sec and
59°C for 1 min for 40 cycles. Quantification was performed
using a standard curve from pBR322-HPV16 plasmid that
contains the entire genome of HPV-16 with a dilution
series from 1 × 103 to 1 × 109 copy number, employing the
program created by Andrew Staroscik (2004) (http://cels.
uri.edu/gsc/cndna.html). As positive control, the SiHa cell
line containing 1–2 copies of HPV-16 per cell was used. To
generate the standard curve GAPDH gene fragment cloned
into pJET1.2/blunt plasmid was used, with 300 nM of each
primer: GAPDH-Reverse: ATGGGTGGAATCATATTGG
AAC, and GAPDH-Forward: GAAGGTCGGAGTCAACG
GATTT. PCR conditions were 95°C for 30 sec and
60°C for 1 min for 40 cycles. The amount of GAPDH
DNA present in each sample was divided by the
weight of one genome equivalent (6.6 pg per cell) and
a factor of 2 (two copies of the GAPDH DNA/gen-
ome equivalent or cell) to obtain the number of gen-
ome equivalents per cell [20]. This sensitive method
can detect ≤1 HPV-E6 copy per 104 cells.Immunohistochemistry for epidermal growth factor
receptor (EGFR), estrogen, progesterone, and Her-2/neu
receptors
Immunohistochemical studies were performed on 4 μm
paraffin sections employing a Ventana automated immu-
nostainer (Tucson, AZ, USA), according to the company’s
protocol with minor modifications (Table 1). Estrogen
(ER) and Progesterone (PgR) receptor status was recorded
using the H-score continuous scale, according to the nu-
clear intensity index, as described elsewhere [21]. Her-2
/neu overexpression was examined, utilizing the Hercep
Test kit (Dako, Carpinteria, CA, USA) following the man-
ufacturer’s instructions. Control cell lines provided by themanufacturer (Dako) were used as negative and positive
controls.
Statistical analysis
After descriptive statistics, the association of continuous
or categorical variables with HPV status was tested by
the Student t test or the Chi square test, as appropriate.
Two-tailed statistics were considered in all cases, and
a probability value of 0.05 or lower was considered as
significant. The SPSS version 20 software (IBM, Inc.,
Armonk, NY, USA, 2011) for MAC was employed for all
computations.
Results
We examined 20 metaplastic breast carcinomas from
Mexican female patients, during a 16-year period (1995–
2008). Mean age of the patients was 49 years (range, 24–73
years). HPV DNA was detected in eight of 20 (40%) meta-
plastic breast carcinomas: HPV-16 in seven (87.5%) cases,
and HPV-18 in one (12.5%) case of matrix-producing bone
carcinoma. Distribution of histological subtypes according
to HPV status, is summarized in Table 2 (Figures 1 and 2).
Mean age of HPV-positive cases was 49 years (range
24–72 years), with the same mean age for HPV-negative
cases (range, 30–73 years). All cases were negative for ER
(Figure 3), and all but one HPV-negative carcinoma with
squamous differentiation (H-score index: 30), were negative
for PgR; 19 cases did not overexpress the HER2 receptor.
Following the Hercep Test criteria, the immunoreactions
were negative (0) in all but one HPV-positive spindle cell
carcinoma, in which a score of 2+ (complete but moderate
staining of >10% of tumor cells) was recorded; however,
Fluorescence in situ hybridization (FISH) for detecting the
gene amplification was not performed. On the other hand,
all cases were positive for EGFR 1 (EGFR, ErbB1, HER1)
(Figure 4), and all but one carcinoma with chondroid meta-
plasia, for cytokeratins 5/6. Tumor size ranged from 2 × 2
cm–11.5 × 7cm (mean size 5.4 × 4.1 cm). On taking into
account the longer measurement of the tumors, HPV-
negative were larger than those HPV-positive metaplastic
carcinomas (6.6 vs. 3.7 cm) (p = 0.042). Regardless of its
relationship with breast tumors, nine women had previous
medical history of at least one cervical smear for screening
purposes, as part of the National campaign against
Table 2 Human papillomavirus (HPV)-positive and -negative metaplastic breast carcinomas
Histology HPV-16 HPV-18 HPV– Total
Carcinoma with chondroid differentiation 3 0 3 6
Adenosquamous carcinoma 2 0 0 2
Carcinoma with squamous differentiation 1 0 4 5
Spindle cell carcinoma 1 0 0 1
Matrix-producing bone carcinoma 0 1 0 1
Carcinoma with squamous/chondroid differentiation 0 0 2 2
Carcinoma squamous/sarcomatoid 0 0 1 1
Carcinoma with chondroid/osteoid differentiation 0 0 1 1
Carcinosarcoma 0 0 1 1
Total 7 1 12 20
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fection appeared in a case of HPV-positive adenosquamous
carcinoma, and in one HPV- negative squamous cell/
sarcomatoid carcinoma, whereas in the remaining seven
cases, the result was reported according to the Bethesda
System as negative for intraepithelial lesion or malignancy.
Viral loads were constantly low, ranging from 0.02040313
(metaplastic carcinoma with chondroid differentiation)–
1.015210939 (metaplastic carcinoma with squamous differ-
entiation) copies/cell (geometric mean, 0.20892 copies/cell),
when compared with number of HPV copies/cell in the cell
line SiHa (3.985 copies/cell) (Table 3) (Figure 5). Tumor-
node-metastasis (TNM) status, age at menarche, meno-
pausal status, relapse, and survival did not show statistically
significant differences between HPV-positive and -negative
metaplastic carcinomas (Table 4).
Discussion
In this study, high-risk HPV DNA was detected in eight of
20 (40%) metaplastic carcinomas of the mammary gland.Figure 1 Area of squamous differentiation in a human
papillomavirus (HPV)-16-positive adenosquamous metaplastic
breast carcinoma (Case 7). (Hematoxylin and eosin stain [H&E];
Original magnification 200×).HPV-16 was found in seven of these (87.5%), whereas
HPV-18 was present in the remaining case (12.5%). Distri-
bution of the HPV genotype is in accordance with previ-
ous Mexican studies in which HPV-16 was the
commonest HPV detected among breast carcinoma
[20,22]. According to surrogate immunohistochemical
profile, nearly all cases fall into the category of “triple
negative” tumors, which form part of the spectrum of
basal-like breast carcinomas. To the best of our know-
ledge, this is the first study to search for high-risk HPV
DNA in metaplastic carcinomas of the female mammary
gland among Latin American women, and the second
reported among other female populations worldwide. The
range of association of HPV and conventional breast can-
cer has been reported as between 0 [23,24] and 86% [25];
such differences have been attributed to several factors in-
cluding variations in the sensitivity of the PCR methods
employed for detecting HPV DNA sequences, according
to the quality of DNA and tissue preservation, variations
in the prevalence rate of HPV infection among differ-
ent countries and among different regions of the sameFigure 2 Human papillomavirus (HPV)-negative metaplastic
carcinoma showing a chondroid matrix. (Hematoxylin and eosin
stain [H&E]; Original magnification 200×).
Figure 3 A case of a human papillomavirus (HPV)-16-positive,
estrogen receptor (ER)-negative breast metaplastic carcinoma
with chondroid differentiation, is illustrated (Case 1). Note the
absence of brown colouration in the neoplastic cell nuclei,
indicating the lack of ER immunoreactivity (anti-ER antibody,
clone1D5). (Immunohistochemistry [IHC]; Original
magnification 200×).
Table 3 Human papillomavirus (HPV)-16 copy numbers in
metaplastic breast carcinomas
Case Histology Copies/Cell
1 Carcinoma with chondroid differentiation 0.132381228
2 Carcinoma with chondroid differentiation 0.266043488
3 Adenosquamous carcinoma 0.439347287
4 Carcinoma with squamous differentiation 1.015210939
5 Spindle cell carcinoma 0.842123643
6 Carcinoma with chondroid differentiation 0.020403130
7 Adenosquamous carcinoma 0.064370642
SiHa Control 3.985001042
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among worldwide population. Interestingly, in this study
the prevalence of HPV-positive metaplastic carcinomas
were higher in comparison with previously reported in
Mexican non-metaplastic carcinomas (40 vs. 10%) [20].
HPV viral loads have not been extensively studied in
breast carcinoma; in previous studies [20,26], the esti-
mated viral loads for HPV-16 in breast neoplastic and
non- neoplastic adjacent tissues were low (<1copy/cell),
rendering it unlikely that even integrated HPV is involved
in breast carcinogenesis. In esophageal squamous cell car-
cinoma, another malignant neoplasm probably associated
with HPV infection, it is also unlikely that low viral loadsFigure 4 A case of human papillomavirus (HPV)-negative
metaplastic breast carcinoma is shown. Brown colouration of
neoplastic cell membranes denotes extensive Epidermal growth
factor receptor (EGFR) immunoreactivity (anti-EGFR antibody,
clone DAK-H1-1197). (Immunohistochemistry [IHC]; Original
magnification 200×).have a leading role in the mechanism of carcinogenesis as
in cervical cancer [27]. Notwithstanding the low viral loads
found again in the present study, these were higher than
in the non-metaplastic carcinomas reported previously
[20,26]. It was also suggested that high-risk HPV DNA
could be acquired and integrated into mammary cells,
once breast neoplastic transformation takes place, prob-
ably during early events of neoplastic development (i.e.
preclinical stage), thus modifying the course of breast car-
cinoma [20]. Interestingly, there are contradictory findings
regarding the presence of HPV in non- malignant breast
conditions: HPV traces have been found in two mammary
fibroadenomas [28] and HPV-18, in three normal breast
reduction specimens [29], whereas in other studies, HPV
DNA has not been isolated from benign breast conditions
or mammoplasty specimens [22,30]; its presence in the
breast fluids has been a controversial issue, as well [31-33].
On the other hand, HPV DNA is also detected in normal
mammary gland tissues adjacent to breast carcinomas
[20,34]. In an experimental study, the cell’s invasive and
metastatic abilities were induced by transfecting two non-
invasive breast cancer cell lines (MCF7 and BT20) with
E6/E7 of HPV-16, in comparison with the same non-
transfected, non-invasive breast cancer cell lines [35]. Con-
trary to this finding but of great interest in this study,
is the fact that HPV-positive were smaller than HPV-
negative metaplastic breast carcinomas, a feature reported
to be associated with a better prognosis in Australian
women, mainly because these are early stage tumors [36].
Indeed, the smaller size of the HPV- positive metaplastic
breast carcinomas comprises the only variable that reached
statistical significance in this and in similar previous stud-
ies carried out in Mexican women [20,22], suggesting that
HPV could modify, as previously stated, the course of
metaplastic breast carcinoma and, as a paradoxical effect,
by means of improving the clinical outcome. This para-
doxical effect is also present in HPV-associated oropharyn-
geal [37] and lung carcinomas [38]. In the case of lung
carcinomas, favorable prognosis of HPV-associated car-
cinomas has been attributed to high Langerhans-cell
Figure 5 Copy numbers of human papillomavirus (HPV)/cell. This graph shows the copy number of E6-HPV-16 genes per cell, in metaplastic
carcinomas. Each copy of the E6 gene is equivalent to an HPV genome.
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tissue remains unsolved. Because the life cycle of HPV oc-
curs in epithelial layers, bloodstream viremia is not an
expected event. However, high-risk HPV DNA has been
isolated in the peripheral circulating mononuclear cells
from females harboring cervical cancer [39], from pediatric
patients infected with Human immunodeficiency virusTable 4 Clinical characteristics of patients according to
HPV status
Factor HPV – (n = 12) HPV + (n = 8) p
Age 49 (14.5) 48.9 (14.3) 0.98
Tumor size (longer) 6.6 (3.4) 3.7 (1.9) 0.042
Tumor side
Left 7 2 0.14
Right 5 6
Histological grade
Moderate 0 2 0.15
Poor 12 6
T classification




N0 7 3 0.65
N1 5 5
TNM Stage
II 5 3 0.85
III 7 5
Recurrence
No 8 4 0.65
Yes 4 4
Overall survival NR 95.7 0.79
HPV: Human papillomavirus; – negative; + positive; p: Probability value. Overall
survival is described in median values (months); NR: Median not reached.(HIV) and healthy donors [40], and from healthy males
[41], raising the possibility that HPV DNA could reach the
transformed breast cells from a previous or transient cer-
vical HPV infection, even in women with a subclinical
infection, through the circulating blood. We previously
suggested that the presence of HPV DNA sequences in
breast tissues and breast carcinomas could be related with
changes in the level of expression of integrins, particularly
with that of the α-6 integrin [20], but also of Heparan sul-
fate proteoglycans (HSPG) [42], which are putative candi-
dates for HPV cell receptors [43].
On the other hand, it was also suggested that metaplas-
tic carcinomas, together with less differentiated breast car-
cinomas, represent the progenitor/stem-cell end of the
spectrum in which breast carcinomas could be arranged,
according to different protein expression patterns and
(cyto)genetic alteration patterns [44]. Within the MCF7
breast-cancer cell line, a stem cell-like subpopulation has
been characterized by overexpression of the adhesion mol-
ecule α-6 integrin [45]. Considering this, it is expected that
carcinomas arising from progenitor/stem cells, are more
likely to express higher levels of α-6 integrin and HSPG,
thus rendering a higher frequency of HPV-DNA among
the neoplastic cells. Indeed, syndecan-1 and syndecan-4,
two cell surface HSPG that have recently been character-
ized as markers of aggressiveness in breast carcinoma, are
overexpressed in estrogen-negative and highly proliferative
carcinomas of the mammary gland [41,46,47]. Metaplastic
breast carcinomas are consistently negative for ER, PgR
and Her-2/neu but positive for EGFR, as in nearly all of
our cases. It is noteworthy that the majority of HPV-
associated carcinomas reported in the literature are closely
related with the “triple-negative” profile. In the study of
Kroupis et al. [48] HPV-positive carcinomas tend to
be poorly differentiated carcinomas (grade III), less
ER-positive, and more proliferative carcinomas. Finally,
metaplastic breast carcinoma is more common among
African-American and Hispanic women in the U.S. [2] and
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in the Mexican patients of this study (61.2 vs. 49 years), a
feature probably related with the exposure to an unfavor-
able and riskier environment at an earlier age, including
HPV infection. Limitation of the study must be seen in the
fact that the sample size is low, due to the rarity of meta-
plastic breast carcinoma, as in Mexico, as worldwide. Be-
cause of the small number of cases in this study, levels of
statistics significance should be interpreted cautiously.
Conclusions
High-risk HPV has been strongly associated with con-
ventional breast carcinomas, although the subtle mech-
anism of neoplastic transformation is poorly understood.
In Mexican patients, the prevalence of HPV infection
among metaplastic breast carcinomas is higher than in
non-metaplastic ones, as so the HPV viral loads; not-
withstanding, HPV viral loads show wide variation and
remain even lower than cervical and other non-cervical
carcinomas, making it difficult to assume that HPV
could play a key role in breast carcinogenesis. Further
studies are warranted to elucidate the meaning of the
presence of high-risk HPVDNA in breast carcinomas.
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